MX2018002857A - Arnip y su uso en metodos y composiciones para la inhibicion de la expresion del gen nrarp. - Google Patents

Arnip y su uso en metodos y composiciones para la inhibicion de la expresion del gen nrarp.

Info

Publication number
MX2018002857A
MX2018002857A MX2018002857A MX2018002857A MX2018002857A MX 2018002857 A MX2018002857 A MX 2018002857A MX 2018002857 A MX2018002857 A MX 2018002857A MX 2018002857 A MX2018002857 A MX 2018002857A MX 2018002857 A MX2018002857 A MX 2018002857A
Authority
MX
Mexico
Prior art keywords
expression
diabetic
inhibiting
methods
retinopathy
Prior art date
Application number
MX2018002857A
Other languages
English (en)
Inventor
Martinez Tamara
Isabel Jimenez Ana
PAÑEDA Covadonga
Original Assignee
Sylentis Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis Sau filed Critical Sylentis Sau
Publication of MX2018002857A publication Critical patent/MX2018002857A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3235—Chemical structure of the sugar modified ring structure having the O of the ribose replaced by another atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a moléculas de ARNip y a su uso en métodos y composiciones farmacéuticas para la inhibición de la expresión del gen NRARP. La invención también se refiere al uso de tales moléculas de ARNip en el tratamiento y/o la prevención de una enfermedad o trastorno relacionado con la neovascularización caracterizado por una mayor expresión y/o actividad del gen NRARP, tal afección del ojo se selecciona del grupo que comprende degeneración macular asociada a la edad (AMD), retinopatía isquémica, edema macular diabético (DME), retinopatía diabética proliferativa (PDR), isquemia retiniana diabética (DRI), edema retiniano diabético (DRE) y retinopatía de prematuridad (ROP) y combinaciones de las mismas.
MX2018002857A 2015-09-08 2016-09-07 Arnip y su uso en metodos y composiciones para la inhibicion de la expresion del gen nrarp. MX2018002857A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382440 2015-09-08
PCT/EP2016/071122 WO2017042238A1 (en) 2015-09-08 2016-09-07 Sirna and their use in methods and compositions for inhibiting the expression of the nrarp gene

Publications (1)

Publication Number Publication Date
MX2018002857A true MX2018002857A (es) 2018-09-12

Family

ID=54199152

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002857A MX2018002857A (es) 2015-09-08 2016-09-07 Arnip y su uso en metodos y composiciones para la inhibicion de la expresion del gen nrarp.
MX2022000554A MX2022000554A (es) 2015-09-08 2018-03-07 Arnip y su uso en metodos y composiciones para la inhibicion de la expresion del gen nrarp.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000554A MX2022000554A (es) 2015-09-08 2018-03-07 Arnip y su uso en metodos y composiciones para la inhibicion de la expresion del gen nrarp.

Country Status (16)

Country Link
US (1) US10752896B2 (es)
EP (1) EP3347470A1 (es)
JP (3) JP6946297B2 (es)
KR (2) KR20180039760A (es)
CN (2) CN108026530B (es)
AU (1) AU2016319072B2 (es)
CA (1) CA2997648A1 (es)
CO (1) CO2018003596A2 (es)
HK (1) HK1257658A1 (es)
IL (2) IL295206B2 (es)
MA (1) MA44908A (es)
MX (2) MX2018002857A (es)
MY (1) MY185638A (es)
RU (1) RU2738971C2 (es)
SG (1) SG10202002084UA (es)
WO (1) WO2017042238A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6577599B2 (ja) 2015-12-15 2019-09-18 日立オートモティブシステムズ株式会社 車両用制御装置

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
HU230458B1 (hu) 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
WO2003068961A2 (en) * 2002-02-13 2003-08-21 Axordia Limited Method to modify differentiation of pluripotential stem cells
AU2003260370B2 (en) 2002-08-05 2008-05-22 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
WO2005062937A2 (en) 2003-12-22 2005-07-14 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
GB0521716D0 (en) 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US20100292301A1 (en) 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
EP2231168A4 (en) 2007-10-03 2012-01-04 Quark Pharmaceuticals Inc NEW STRUCTURES OF ARNSI
NZ591391A (en) 2008-10-22 2012-10-26 Quark Pharmaceuticals Inc Non-invasive methods for treating eye disorders using a topical oligonucleotide composition
EP2358877A2 (en) * 2008-11-21 2011-08-24 Reliance Life Sciences Pvt., Ltd. Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa
MX2012001716A (es) * 2009-08-14 2012-04-02 Genentech Inc Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
US9260470B2 (en) 2009-11-04 2016-02-16 Sungkyunkwan University Foundation For Corporate Collaboration SiRNA structure for minimizing off-target effects caused by antisense strands, and use thereof
EP2390327A1 (en) * 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
WO2012140234A1 (en) * 2011-04-13 2012-10-18 Vib Vzw Modulation of mirna in diseases with aberrant angiogenesis
US20130123330A1 (en) 2011-07-15 2013-05-16 Patrick Y. Lu Dual Targeted siRNA Therapeutics for Treatment of Diabetic Retinopathy and Other Ocular Neovascularization Diseases
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
KR20140085790A (ko) * 2012-12-27 2014-07-08 한화케미칼 주식회사 Ｎｏｔｃｈ 신호전달을 효과적으로 저해하는 ｄｌｌ４에 특이적인 신규한 인간 단일클론항체
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
EP2865756A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
EP2865757A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
CN105624159B (zh) * 2016-02-22 2019-02-05 中国人民解放军第二军医大学 一种针对人EDIL3基因的siRNA及其应用

Also Published As

Publication number Publication date
AU2016319072A1 (en) 2018-03-15
JP2022000035A (ja) 2022-01-04
CA2997648A1 (en) 2017-03-16
JP2023144029A (ja) 2023-10-06
US10752896B2 (en) 2020-08-25
JP6946297B2 (ja) 2021-10-06
IL257524A (en) 2018-04-30
RU2018112453A3 (es) 2020-05-18
CN114632090A (zh) 2022-06-17
IL295206B2 (en) 2024-02-01
MY185638A (en) 2021-05-27
AU2016319072B2 (en) 2022-03-17
IL295206B1 (en) 2023-10-01
SG10202002084UA (en) 2020-05-28
KR20180039760A (ko) 2018-04-18
JP2018526031A (ja) 2018-09-13
CN108026530B (zh) 2022-03-04
KR20240000615A (ko) 2024-01-02
MX2022000554A (es) 2022-02-10
CO2018003596A2 (es) 2018-08-31
RU2018112453A (ru) 2019-10-10
CN108026530A (zh) 2018-05-11
JP7394815B2 (ja) 2023-12-08
MA44908A (fr) 2018-07-18
RU2738971C2 (ru) 2020-12-21
IL295206A (en) 2022-10-01
HK1257658A1 (zh) 2019-10-25
EP3347470A1 (en) 2018-07-18
IL257524B1 (en) 2023-09-01
IL257524B2 (en) 2024-01-01
WO2017042238A1 (en) 2017-03-16
US20180340177A1 (en) 2018-11-29
CN114632090B (zh) 2023-09-29

Similar Documents

Publication Publication Date Title
SG10201903290YA (en) Modified double-stranded rna agents
MX2016009331A (es) Composiciones y metodos para tratar enfermedades oculares.
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
MX2013003890A (es) Composiciones y metodos para tratar edema ocular, neovascularizacion y enfermedades relacionadas.
MX2017012426A (es) Composiciones y metodos para modular la expresion de tmprss6.
BR112014008759A2 (pt) tratamento de doença ocular
EA201990644A1 (ru) Антисмысловые олигонуклеотиды для лечения глазного заболевания
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
MX2015008697A (es) Tratamiento contra la degeneración macular relacionada con la edad.
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
WO2014022739A3 (en) Modified rnai agents
MX2015012435A (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
CL2014002523A1 (es) Compuestos derivados de piridina , piperidina y pirrol sustituidos, inhibidores de ccr3; uso para el tratamiento de enfermedades seleccionadas de degeneracion macular relacionada con la edad, retinopatia del prematuro, oclusion venosa retinal central, poliposis nasal, esofagitis y/o gastroenteritis eosinofilica, entre otras
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
NZ746468A (en) Methods of treating ocular conditions
EP4276199A3 (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
MX2018001126A (es) Oligonucleotidos terapeuticos.
MY201535A (en) Therapeutic compounds
MX2022000554A (es) Arnip y su uso en metodos y composiciones para la inhibicion de la expresion del gen nrarp.
TN2018000122A1 (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
MX368084B (es) siRNA Y SU USO EN LA PREPARACIÓN DE UN MEDICAMENTO PARA USARSE EN UN MÉTODO PARA EL TRATAMIENTO DE UN TRANSTORNO OCULAR.
MX2020001274A (es) Fotoregulina3, moduladora de los genes de los fotorreceptores para el tratamiento de enfermedades de la retina.
WO2018048046A3 (ko) mTOR 저해제를 함유하는 황반변성 치료용 의약조성물